Publication | Open Access
The P681H mutation in the Spike glycoprotein confers Type I interferon resistance in the SARS-CoV-2 alpha (B.1.1.7) variant
25
Citations
39
References
2021
Year
Unknown Venue
Lung InflammationViral PathogenesisImmunologyMolecular BiologyInnate ImmunityViral Structural ProteinCovid-19Alpha SpikeSpike GlycoproteinSars-cov-2 AlphaViral GeneticsMolecular SignalingP681h MutationVirologyPathogenesisSummary VariantsVirus-host InteractionSpike Glycoprotein ConfersMedicineViral Immunity
SUMMARY Variants of concern (VOCs) of severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2) threaten the global response to the COVID-19 pandemic. The alpha (B.1.1.7) variant appeared in the UK became dominant in Europe and North America in early 2021. The Spike glycoprotein of alpha has acquired a number mutations including the P681H mutation in the polybasic cleavage site that has been suggested to enhance Spike cleavage. Here, we show that the alpha Spike protein confers a level of resistance to the effects of interferon-β (IFNβ) in lung epithelial cells. This correlates with resistance to restriction mediated by interferon-induced transmembrane protein-2 (IFITM2) and a pronounced infection enhancement by IFITM3. Furthermore, the P681H mutation is necessary for comparative resistance to IFNβ in a molecularly cloned SARS-CoV-2 encoding alpha Spike. Overall, we suggest that in addition to adaptive immune escape, mutations associated with VOCs also confer replication advantage through adaptation to resist innate immunity.
| Year | Citations | |
|---|---|---|
Page 1
Page 1